Urolithin A induces mitophagy and prolongs lifespan in C. elegans and improves rodent muscle (Ryu et al., 2016)
Animal healthspan / lifespan study
Record verify: verified against primary source
| Design | Preclinical mitophagy + lifespan/function study (C. elegans + rodent) |
| DOI | 10.1038/nm.4132 |
| Citation status | doi verified via Crossref 2026-07-12 (Nat Med 2016;22(8):879-888, Ryu et al., 'Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents'). PMID is not confirmed; see identifier status. |
Identifiers: DOI verified; PMID not reported; trial registry id not applicable to this study type. Record-level verification and identifier-level status are separate: a record can be verified against its primary publication on one identifier while another is simply not confirmed. No identifier is fabricated, and none is left in a “pending” state.
Five-qualifier claim
| Species / population | C. elegans and rodents (mouse/rat). |
| Exposure, route, schedule | Dietary urolithin A. |
| Comparator / duration | Vehicle/untreated controls. |
| Endpoint / numeric result | Induced mitophagy, prolonged lifespan in C. elegans, and improved muscle function in rodents — the preclinical basis for the urolithin A program. |
| What it did NOT establish | Invertebrate lifespan and rodent muscle gains are animal results; they do not establish any human lifespan or healthy-aging effect. |
Interventions
What this trial administered
These are the compounds this trial administered, nothing more. MitoiX does not rank products, name a best one, or suggest a dose — read the record above and the primary reference, then talk to a clinician.
- Urolithin A (Mitopure) — Urolithin A (Mitopure)
Studied form: Mitopure, 500-1000 mg/day in the human trials
Find Urolithin A (Mitopure) on Amazon →
Links marked with an arrow are affiliate links: MitoiX may earn a commission if you buy through them, at no extra cost to you. This never affects what is published — see the affiliate disclosure.
Primary reference
https://doi.org/10.1038/nm.4132
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status names the source and the date. An identifier that is not confirmed is named as such in the identifier row above, never filled in from a secondary source.